Lastly, we did not observe differences in event-free survival between the 2002- and 2017-HF cohort, although patients from the 2017-cohort showed lower levels of NT-proBNP and were more likely to receive guideline-recommended therapies with β-blockers and cardiac devices. This evidence concerns the gene NPPB and hydrops fetalis.